Next Article in Journal
Five New Alkaloids from the Stem Bark of Daphniphyllum macropodum
Next Article in Special Issue
Role of MicroRNA in Response to Ionizing Radiations: Evidences and Potential Impact on Clinical Practice for Radiotherapy
Previous Article in Journal
Microwave-Assisted Extraction of Herbacetin Diglucoside from Flax (Linum usitatissimum L.) Seed Cakes and Its Quantification using an RP-HPLC-UV System
Previous Article in Special Issue
Clinical Application of MicroRNA Testing in Neuroendocrine Tumors of the Gastrointestinal Tract
Open AccessArticle

Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients

1
Tumor Genomics Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, Milan 20133, Italy
2
Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, via Venezian 1, Milan 20133, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 17 February 2014 / Revised: 28 February 2014 / Accepted: 4 March 2014 / Published: 10 March 2014
(This article belongs to the Special Issue miRNAs as Probes to Monitor Cancer and Neurodegenerative Disorders)
Lung cancer is the most common cause of cancer deaths worldwide and numerous ongoing research efforts are directed to identify new strategies for its early detection. The development of non-invasive blood-based biomarkers for cancer detection in its preclinical phases is crucial to improve the outcome of this deadly disease. MicroRNAs (miRNAs) are a new promising class of circulating biomarkers for cancer detection and prognosis definition, but lack of consensus on data normalization methods for circulating miRNAs and the critical issue of haemolysis, has affected the identification of circulating miRNAs with diagnostic potential. We describe here an interesting approach for profiling circulating miRNAs in plasma samples based on the evaluation of reciprocal miRNA levels measured by quantitative Real-Time PCR. By monitoring changes of plasma miRNA-ratios, it is possible to assess the deregulation of tumor-related miRNAs and identify signatures with diagnostic and prognostic value. In addition, to avoid bias due to the release of miRNAs from blood cells, a miRNA-ratios signature distinguishing haemolyzed samples was identified. The method described was validated in plasma samples of lung cancer patients, but given its reproducibility and reliability, could be potentially applied for the identification of diagnostic circulating miRNAs in other diseases. View Full-Text
Keywords: miRNAs; biomarkers; early diagnosis; lung cancer; real-time PCR; haemolysis miRNAs; biomarkers; early diagnosis; lung cancer; real-time PCR; haemolysis
Show Figures

Figure 1

MDPI and ACS Style

Fortunato, O.; Boeri, M.; Verri, C.; Conte, D.; Mensah, M.; Suatoni, P.; Pastorino, U.; Sozzi, G. Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients. Molecules 2014, 19, 3038-3054. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules19033038

AMA Style

Fortunato O, Boeri M, Verri C, Conte D, Mensah M, Suatoni P, Pastorino U, Sozzi G. Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients. Molecules. 2014; 19(3):3038-3054. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules19033038

Chicago/Turabian Style

Fortunato, Orazio; Boeri, Mattia; Verri, Carla; Conte, Davide; Mensah, Mavis; Suatoni, Paola; Pastorino, Ugo; Sozzi, Gabriella. 2014. "Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients" Molecules 19, no. 3: 3038-3054. https://0-doi-org.brum.beds.ac.uk/10.3390/molecules19033038

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop